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We investigated the effects on assembly and antigenic properties of speciﬁc modiﬁcations of the
transmembrane spanning (TMS) and cytoplasmic tail (CT) domains of HIV-1 Env from a transmitted/
founder (T/F) ZM53 Env glycoprotein. A construct containing a short version of the TMS domain derived
from the mouse mammary tumor virus (MMTV) Env with or without a GCN4 trimerization sequence in
the CT exhibited the highest levels of incorporation into VLPs and induced the highest titers of anti-Env
IgG immune responses in a VLP context. Sera from guinea pigs immunized by VLPs with high Env
content, and containing the CT trimerization sequence, had increased neutralization activity and anti-
body avidity. A cross-clade prime-boost regimen with clade B SF162 or clade C ZM53 Env DNA priming
and boosting with VLPs containing modiﬁed ZM53 Env further enhanced these immune responses. The
modiﬁed VLPs demonstrate improved potential as HIV-1 vaccine antigens.
& 2016 Published by Elsevier Inc.Introduction
Induction of an antibody response capable of preventing
infection by various HIV-1 isolates is a critical goal for vaccines
that will protect against HIV-1 infection (Doria-Rose, 2010; Sta-
matatos et al., 2009). Broadly neutralizing antibodies can prevent
HIV-1 infection via binding to envelope (Env) glycoprotein com-
plexes on the virion surface (Burton et al., 2011, 2012), and the
HIV-1 Env spike is the most important viral antigen for antibody-
based vaccine design. However, the Env gp120 subunit contains a
number of features that enable it to evade humoral immunity
including variable loops, N-linked glycosylation, and conforma-
tional ﬂexibility (Douek et al., 2006; Go et al., 2008). The natural
viral membrane context may be important to maintain a fully
native Env trimer conformation (Chen et al., 2015). VLP vaccines
presenting native trimeric HIV-1 spikes have been explored, but
none have yet demonstrated a high potential to induce neu-
tralizing antibodies even against moderately sensitive (tier 2)
strains of HIV-1 (Tong et al., 2014).þ1 404 727 8250.
.
gy, Wuhan Institute of Virol-
ubei, China.Previous studies have shown that truncation of the cytoplasmic
tail of the SIV envelope glycoprotein increases Env incorporation
into virions (Johnston et al., 1993; Zingler and Littman, 1993).
Moreover, it was found that the truncated Env proteins have the
ability to self-associate on the cell surface and are assembled into a
more closely packed array than FL Env (Vzorov and Compans,
1996, 2000). Substitution of the HIV TMS-CT with sequences
derived from other viral glycoproteins, such as the mouse mam-
mary tumor virus envelope glycoprotein, was found to enhance
Env incorporation into VLPs (Wang et al., 2007). Using a leucine
zipper trimerization sequence from the yeast GCN4 transcription
factor, trimeric forms of target proteins can be stably expressed
(Vzorov and Compans, 2011; Waning et al., 2004; Weldon et al.,
2011). Stabilized Env trimers may avoid “immune misdirection”
and induction of non-neutralizing antibody responses resulting
from exposure of non-native epitopes on monomeric and dimeric
forms of Env (Moore et al., 2006; Tong et al., 2012). Based on these
reports, we compared Env constructs with a modiﬁed leucine
zipper GCN4 trimerization sequence to stabilize the trimeric Env
structure, and with MMTV membrane-anchoring sequences to
increase the incorporation of Env into VLPs containing ZM53
(clade C) Env. The results indicate that HIV VLPs incorporating high
levels of conformation-stabilized Env exhibit enhanced immuno-
genicity and may be useful for further development of a prophy-
lactic HIV vaccine.
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Design of modiﬁed Env proteins
Previously, chimeric HIV-1 Env with TMS-CT domains derived
from mouse mammary tumor virus (MMTV) exhibited enhanced
Env incorporation into VLP and represent promising immunogen
for developing an effective vaccine (Wang et al., 2007). In the
present study CCR5-tropic clade B SF162 and a transmitted/foun-
der (T/F) ZM53 Env glycoproteins were used as immunogens for
DNA priming. For boosting, VLPs containing modiﬁed ZM53 Env
were used. We compared different modiﬁcations of the MMTV
TMS-CT domains and additional modiﬁcations of CT domain.
Based on analysis of Env expression and incorporation into VLPs,
constructs were selected for immunization studies and are shown
schematically in Fig. 1.
Modiﬁcations of the TMS region
To develop more effective VLP immunogens, we compared TMS
domain modiﬁcations for enhancement of Env incorporation into
VLPs (Wang et al., 2007) and CT domain modiﬁcations for induc-
tion of conformational changes in the gp120 subunit (Vzorov and
Compans, 2011; Vzorov et al., 2005). It was previously observed
that a chimeric Env with substitution of the HIV TMS-CT with a
sequence derived from MMTV Env exhibited enhanced incor-
poration into VLPs (Wang et al., 2007). We compared additional
TMS modiﬁcations and determined their effects on the incor-
poration of trimeric Env into VLPs. We initially compared SIV-
mac239 Env constructs (Table 1) with replacements of the TMS
with a heterologous TMS or with different modiﬁcations in the
TMS region (Table 2). Modiﬁed env genes in plasmids containing
sequences coding the external sequences of SIVmac239 Env pro-
teins were expressed in Hep2 cells. Because SIVmac239 Env can
exhibit naturally truncated forms, it is a convenient model to test
effects of different structural modiﬁcations on Env functions. The
effects of the TMS domain on total Env expression and cell surfaceTMS22-hb CT22 R+ 
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Fig. 1. Schematic diagrams and designations of modiﬁed Env. HIV-1 Envs were modiﬁ
modiﬁed MMTV22 (TMS-CT region) in which Met (M25) was replaced by positively charg
construct was designated – TMS22-hb. (B) Schematic diagrams and designations of othexpression levels were measured by radioactive metabolic label-
ling followed by surface labeling and immune precipitation. The
surface expression level relative to wild type (WT) was calculated
for each modiﬁed Env by phosphorimager analysis. Generally, the
modiﬁed Env constructs exhibited higher levels of surface
expression ranging from 114 to 170% of the FL SIVmac239 Env
(Fig. 2a). Because the TMS domain has a conserved organization
and length (22 aa) among HIV and SIV Env proteins, a shortened
22 aa version of the MMTV TMS-CT domain was compared and
further modiﬁed by changing Met (M25) to a positively charged
Arg (Rþ) which is conserved in HIV and SIV Envs. The 22 residues
segment of 35 MMTV-derived amino acids was selected based on
sequence comparison with the HIV TMS (Table 2). Modiﬁed Envs
containing other sequence segments from the MMTV TMS exhib-
ited lower levels of surface expression (not shown). The construct
designated TMS22 with a shorter 22 aa version of the MMTV TMS
domain, and containing a positively charged Arg, exhibited the
highest level of surface expression. Env TMS22 also exhibited
higher fusion activity than Env TMS35 with a full-length 35 aa
MMTV TMS domain (Table 1a; Fig. 2b). Taken together the results
indicate that the length and sequence of the TMS domain can be
modiﬁed to improve cell surface expression of Env proteins
without affecting fusion activity of the SU domain.
Modiﬁcations of the CT domain
The cytoplasmic domain is required to enhance Env protein
surface stability (Vzorov and Compans, 2011; Ye et al., 2004). To
examine the effects of modiﬁcations of the CT structure, we
compared the SF162 Env TMS22-hb construct having an addition
of a GCN4 sequence, which is able to form a three helix bundle
(hb), and a construct TMS22-hb3a with a mutant GCN4 sequence,
in which critical isoleucine residues required for formation of a
three-helix structure were changed to alanine. A functional cell–
cell fusion assay indicated that the TMS22-hb construct with the
GCN4 sequence had impaired fusion activity, as also observed
before with SIV Env constructs (Vzorov and Compans, 2011)GCN4
 
GCN4
V-TMS-CT GCN4 -forms a helical bundle (hb)
ed by replacement of TMS and CT domains of ZM53 HIV-1 Env. (A) Sequences of
ed Arg and addition of aa GCN4 sequence to the CT domain with a GSGG linker. The
er constructs used for VLP production and immunization studies.
Table 1
a Env modiﬁcations. TMS domain.
Construct EPa Modiﬁcations Cell surfaced Fusion cell–celle
TMS CT
Type Rþb GGxxGc Length
FL SIV SIV þ  22 SIV FL þþ þþþ
TMS35 SIV MMTV   35 MMTV þþ þ
TMS22 SIV MMTV þ  22 MMTV þþþ þþ
BV SIV BV   23 BV þþ þþ
SV5 SIV SV5   38 SV5 þ 
HA SIV HA   27 HA þþþ 
1b Env modiﬁcations. CT domain
Construct EPa Modiﬁcations Cell surfaced Fusion cell–celle
TMS CT
Type Rþb GGxxGc Length
CT17 HIV-1 HIV þ þ 22 HIV-CT17 þþþ þþþ
TMS22-hb HIV-1 MMTV þ  22 MMTVplus GCN4f þþþ 
TMS22-hb3a HIV-1 MMTV þ  22 MMTVplus GCN4-3ag þþþ þþ
a EP is the extracellular part of Env protein.
b A charged arginine residue (Rþ) could play essential role in transport and assembly of Env trimers (Yue et al., 2009).
c GGxxG motif, which may play role in construction of a framework for the association of TM helixes (Shang et al., 2008).
d Cell surface expression levels are coded as follows: þþþ , 100%¼maximum percent; þþ , o100–50% of the maximum percent; þ , o50% of the maximum
percent.
e R5 positive cell–cell fusion activity and level of incorporation are coded as follows: þþþ , 100%¼maximum percent (Env FL); þþ , o100–50% of the maximum
percent; þ , o50% of the maximum percent.
f The amino acid sequence of GCN4 was derived from GCN-4-p-II (Harbury et al., 1993).
g Mutant GCN4-3a was designed to ablate the isoleucine interactions (Vzorov and Compans, 2011).
Table 2
TMS sequences.
TMS/no. aa Sequence (aa)a No. of positively charged residues
ZM53 (22) IFIMIVGGLIGLRIIFAVLSIV 1
SF162 (22) IFIMIVGGLVGLRIVFTVLSIV 1
SIVmac239 (22) GVYIVVGVILLRIVIYIVQMLA 1
SV5/F (38) TYLSAITSATTTSVLSIIAICLGSLGLILIILLSVVVW
Flu/HA (27) DWMLWISFAISCFLLCVALLGFIMWAC
BV/gp64 (23) FMFGHVVNFVIILIVILFLYCMI
MMTV (35) LNPLDWTQYFIFIGVGALLLVIVLMIFPIVFQCLA
MMTV (26) FIFIGVGALLLVIVLMIFPIVFQCLA
MMTV (22) GVGALLLVIVLMIFPIVFQCLA
MMTV(22)(Rþ) GVGALLLVIVLRIFPIVFQCLA 1
MMTV (26) LNPLDWTQYFIFIGVGALLLVIQCLA
a Letter in boldface represent positively charged residues.
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sequence in the CT domain demonstrated conformational effects
on the Env protein.Production of HIV-1 VLPs with modiﬁed Env
Combinations of different immunogens might induce protec-
tive antibody responses with greater breadth and potency. In the
present study we used a transmitted/founder (T/F) ZM53 Env with
a compact structure, including shorter V1–V4 loops (Derdeyn
et al., 2004). As shown in Fig. 4, all the modiﬁed ZM53 Envs were
expressed well on the surfaces of insect cells. Env TMS22-hb with
a trimeric helical bundle structure in the CT domain exhibited
effective incorporation into VLPs (Table 3). The data conﬁrm pre-
vious results (Vzorov and Compans, 1996; Wang et al., 2007) that
the sequences of the TMS-CT domain can modulate the efﬁciency
of Env incorporation into VLPs.Env-speciﬁc antibody responses
To compare speciﬁc antibody responses against VLPs contained
modiﬁed Envs, guinea pigs were primed two times with DNA
vaccines and boosted two times by VLP vaccines with a 4 week
interval between each immunization. Immune sera from I.M.
immunized animals were evaluated for anti- ZM53 Env IgG or
anti-SF162 Env IgG antibody titers using ELISA. Two immunization
groups were used to compare homologous and heterologous
prime-boost regimens. One set (homologous set) was immunized
with ZM53 DNA and ZM53 VLPs. The other (heterologous set) was
ﬁrst immunized with SF162 DNA and then boosted with ZM53
VLPs. The immune responses of the groups against SF162 Env were
different from those against ZM53 Env. The IgG or IgG2 titers were
signiﬁcantly increased against SF162 compared to the FL group in
animals immunized with heterologous prime-boost regimens
within the groups primed with the SF162 DNA vaccine, but not
between groups primed with ZM53 DNA (Fig. 5A–D). Both
homologous and heterologous prime-boost regimens showed
p<0.05
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5. HA (27 aa)
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Fig. 2. Analysis of function of modiﬁed Envs. (A) Expression of modiﬁed Env on the surface of transiently transfected Hep2 cells. Surface expression relative to the wild type
(FL) for each modiﬁed Env was calculated by phosphorimager analysis as described in Materials and methods. Data are plotted as the mean of three experiments. Error bars
represent standard deviations. Asterisks denote signiﬁcant differences in the level of expression of 35 aa-MMTV compared to 22 aa-MMTV (Po0.05 by Unpaired Student t
test). (B) Cell fusion activity of modiﬁed Env. A. NIH3T3 cells were infected with a vaccinia vTF7-3 virus and then transfected by T7 plasmid constructs. 3T3T4R5 cells were
infected with IHD-J vaccinia virus and transfected with a reporter gene construct. At 18 h post-transfection, the two populations were mixed and incubated, after which cell
fusion was quantitated by a colorimetric lysate assay. The data shown are the percentages of the ß-Gal activity observed in WT (FL)-expressing cells. Data are plotted as the
mean of three experiments. Error bars represent standard deviations.
p= 0.0918
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Fig. 3. Analysis of function of Envs with modiﬁed CT domains. (A) Expression of modiﬁed Env on the surface of transiently transfected Hep2 cells. Surface expression relative
to the wild type (CT17) for each modiﬁed Env was calculated by phosphorimager analysis as described in section Materials and ethods. Data are plotted as the mean of three
experiments. Error bars represent standard deviations. Asterisks denote no signiﬁcant differences of the level of expression of TMS22-hb compared to TMS22-hb3a
(P¼0.0918 by Unpaired Student t test). (B) Cell fusion activity of Env with modiﬁed CT domains. The colorimetric lysate assay described in Fig. 1 was used. The data shown
are the percentages of the ß-Gal activity observed in WT (CT17)-expressing cells. Data are plotted as the mean of three experiments. Error bars represent standard deviations.
A.N. Vzorov et al. / Virology 489 (2016) 141–150144signiﬁcantly increased anti-ZM53 Env antibody titers induced by
TMS22 and TMS22-hb constructs compared with other groups
(Fig. 5E–H). The speciﬁc immune responses were low in animals
immunized with truncated CT17 Env VLP (not shown), and were
similar to negative control groups immunized by Gag VLP only or
naïve guinea pigs (Fig. 5). However, the responses against SF162
Env were generally higher than against ZM53 Env. The results also
indicate that the TMS22 and TMS22-hb Env-containing VLPs
induced higher anti-SF162 Env IgG and IgG2 immune responses
with greater breadth using a heterologous prime-boost regimen
and against transmitted/founder ZM53 clade C Env using either
the homologous or heterologous prime-boost regimen.
Neutralization activity induced by immunization with VLPs contain-
ing modiﬁed Env
In order to evaluate the neutralization activity of the immune
sera, a pseudotype virus assay system was used as described(Seaman et al., 2010). The neutralization activity of sera collected
at 2 weeks following the ﬁnal immunization was assayed against
autologous (subtype C, tier 2 ZM53) and subtype C, tier
2 ZM249M.PL; subtype B, tier 1 NL4-3, tier 2 AC10.0.29, and
RHPA4259.7 pseudotyped viruses. As shown in Fig. 6, the neu-
tralization activity of immune sera from animals immunized with
TMS22-hb VLPs in the homologous immunization set was
enhanced against subtype C viruses, and neutralized about 10 and
18% of autologous ZM53 and ZM249M.PL1 pseudotyped viruses,
respectively. In the heterologous immunizations, the neutraliza-
tion activity of immune serum from the TMS22-hb group was
signiﬁcantly enhanced against viruses pseudotyped with B sub-
type Envs, and neutralized about 25% of NL4-3 and AC10.0.29.
Serum from animals immunized with TMS35-hb VLPs neutralized
about 11% of RHPA4259.7 pseudotyped virions. These results
indicate that immunization with VLPs containing the TMS22-hb
Env modiﬁcation and use of a heterologous prime-boost regimen
can induce antibodies with broader neutralization activity.
Fig. 4. Expression of modiﬁed Env. Modiﬁed ZM53Envs were expressed by rBV in Sf9 cells (A,B). Cell surface expression of the membrane-anchored modiﬁed Envs was
detected by cell surface biotinylation in the lower panels (A). For optimization of VLP production, Sf9 cells were infected with rBVs expressing modiﬁed Env and Gag at
different MOI as designated in the Table. VLPs were prepared as described in Materials and methods. The resulting VLPs were analyzed by Western blots (WB) and the
optimal production indicated by boxes. Env and Gag bands were probed with goat anti-HIV-1 gp120 polyclonal antibody and guinea pig anti-gag polyclonal antibody (B).
Table 3
Env content of HIV VLPs.
VLPs ZM53 Env contents (%)a
FL 4
TMS35 5.87
TMS35-hb 2
TMS22 9.6
TMS22-hb 6.8
a Env content relative to the total amount of VLP proteins (100%). VLP com-
positions were determined by ELISA as described before (Wang et al., 2007). The
optimal MOIs of rBVs expressing Env and Gag were 2: 1, 4: 1, 4: 2, 4: 2 and 2: 2 to
produce VLPs containing ZM53-FL, ZM53–TMS35, ZM53–TMS35-hb, ZM53–TMS22,
and ZM53–TMS22-hb, respectively.
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Ab-mediated protection against HIV-1 may be correlated with
avidity of anti-Env antibodies (Zhao et al., 2009). To further char-
acterize the antibody responses in guinea pigs immunized with
DNA/VLP immunogens to conformation-modiﬁed viral envelope
proteins, the serum samples were analyzed for antibody avidity
using the ConA ELISA procedure (Cole et al., 1997). The ELISA
avidity assay was used to determine the envelope-speciﬁc anti-
body avidity index as measured by the relative stability of the
antigen–antibody complexes to a 1.5 M sodium thiocyanate wash.
The heterologous prime-boost regimen induced antibody
responses with signiﬁcantly higher avidity than the homologous
prime-boost regimen (not shown). The group of animals immu-
nized with TMS22-hb VLP produced Abs with avidity indexes
substantially higher than other groups (Fig. 7). Notably, the high
avidity TMS22-hb-VLP elicited Ab also had broader activity for a
panel of clade B and C Envs: NL4-3 (greater than 70%); AC10.0.29
(greater than 50%); RHPA4259.7 (greater than 15%); ZM249M.PL1(greater than 25%); and ZM53 (greater than 25%). The results
indicate that TMS22-hb Env VLPs elicit high-avidity serum anti-
bodies for a range of Env proteins.Discussion
We describe here the properties of a series of VLP-based Env
immunogens, in which the membrane anchor sequences were
systematically modiﬁed. These studies were stimulated by the
previous observation that the level of incorporation of Env into
VLPs could be greatly enhanced by replacing the HIV TMS
sequence with the corresponding region of the MMTV Env protein,
a glycoprotein which is assembled into virions at very high levels
(Wang et al., 2007). The Env TMS sequences of HIV and MMTV
differ in their length and sequences, which were systematically
modiﬁed in the present study. In addition we investigated the
effects of stabilization of the Env trimeric structure on assembly
into VLPs and functional properties.
The resulting constructs were speciﬁcally evaluated for their
ability to enhance induction of neutralizing antibodies and for
antibody avidity. The most straightforward way to produce tri-
meric Env with a native antibody recognizable conformation is to
express it in a membrane context, such as in VLPs. The sequences
of the TM subunit are responsible for Env trimer stability, and the
loss of trimer stability leads to misfolding and dissociation of
gp120–gp41 subunits (Sattentau, 2013). Increased trimer stability
can be introduced by incorporation of a disulﬁde bond linking
gp120 to gp41 in cleaved trimers, termed SOS gp140 (Binley et al.,
2000; Harris et al., 2011; Pugach et al., 2015; Sanders et al., 2002)
or by addition of a trimerization motif to the CT domain (Vzorov
and Compans, 2011). CT modiﬁcation may exhibit effects on the
conformation of gp120 and exposure of antibody-recognizable
epitopes (Edwards et al., 2002; Vzorov and Compans, 2011; Vzorov
et al., 2005; Wyss et al., 2005).
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Fig. 5. Anti-Env IgG isotype-speciﬁc antibody responses. Serum samples from guinea pigs immunized I.M. were evaluated for Abs titers using ELISA on plates coated with
SF162 (A–D) or ZM53 (E–H) Env proteins. Anti-Env IgG isotype speciﬁc antibody responses obtained by immunization with ZM53 DNA and ZM53 VLP (A, B, E, F), obtained by
immunization with SF162 DNA and ZM53 VLP (C, D, G, H). Unpaired Student’s t test indicates a signiﬁcant difference (*Po0.05) between FL group and other groups.
A.N. Vzorov et al. / Virology 489 (2016) 141–150146It was previously shown that replacement of the HIV-1 TMS-CT
with a MMTV TMS-CT domain increased levels of Env incorpora-
tion into VLP up to 10-fold (Wang et al., 2007). Here we modiﬁed
the MMTV TMS domain with a shorter version containing 22 aa,
and found that this Env protein had increased levels of Env
incorporation into VLPs when compared with Env carrying a 35 aa
MMTV TMS domain. A further modiﬁcation was made to change
Met of the MMTV TMS-CT domain to a conserved positively
charged Arg residue as found in HIV-1 and SIV TMS domains, since
a charged arginine residue was reported to be essential for
transport and assembly of HIV-1 and SIV Env trimers (Yue et al.,
2009). In addition, the HIV-1 TMS domain contains a GGxxG motif,
which may provide a framework for the association of TM helixes.
In contrast, the SIV TMS domain lacks this motif. Mutagenesis
studies on the GGxxG sequence present in TMS domain may
severely decreased the fusion activity and incorporation of Env
proteins onto virions, indicating the additional stabilization effect
(Miyauchi et al., 2006). These modiﬁcations may impact other
functions of Env proteins which are not important for Env protein
immunogenicity and were not investigated in our study.
A previous study had shown that a DNA prime-protein boost
protocol induced higher immune responses with a broader range
of neutralization activity in mice and guinea pigs (Muthumani
et al., 2013). In the present study, we also applied a cross-cladeDNA prime-VLP boost approach in order to enhance immune
responses targeted to conserved sequences in HIV Env. Trans-
mitted/founder Envs elicit fewer potent neutralizing antibodies
(Liao et al., 2013). The ﬁnding that higher immune responses
against SF162 Env than against ZM53 Env were observed may be
due to structural differences between these Envs. ZM53 Envs
which exhibit a more compact structure (Cavrois et al., 2014;
Derdeyn et al., 2004) elicited lower, but more speciﬁc immune
responses than SF162Envs. Our data show that guinea pigs
inoculated with VLPs carrying the TMS22-hb-modiﬁed Env, which
exhibits high levels of incorporation and trimer stability, together
with use of a cross-clade immunization regimen with clade B
SF162 Env DNA and boosting with VLPs containing modiﬁed ZM53
Env, resulted in increased neutralization activity and avidity of Abs
against homologous and heterologous Envs including type B and
type C pseudotyped viruses.
These data indicate that a heterologous cross-clade prime-
boost approach, priming with either B or C clade DNA vaccines and
then boosting with clade C VLPs, provides the opportunity for the
immune system to boost responses speciﬁc to conserved epitopes,
thus conferring enhanced cross-clade reactivity. Also, the boost
responses to conserved epitopes were obtained by immunization
with a transmitted/founder Env (ZM53).
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Fig. 6. Neutralization activity of antibody elicited by immunization with VLPs containing modiﬁed Env. Serum samples from immunized guinea pigs were mixed with Envs
of subtype B and C HIV-1 pseudotyped virions at 1:40 dilutions, and neutralization was analyzed in indicator JC53-BL cells as described in Materials and methods. The
percentages of neutralization by each serum sample were calculated and compared. Unpaired Student’s t test indicates a signiﬁcant difference (*Po0.05) between FL group
and other groups.
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modiﬁcations of the Env TMS/CT, together with incorporation into
VLPs can produce antigens which induce broader neutralization
activity and enhanced avidity, and have potential for developing
HIV vaccines with enhanced efﬁcacy. The RV144 trial also showed
that non-neutralizing envelope antibodies might be able to pro-
vide protection from HIV-1 transmission (Haynes et al., 2012).
Non-neutralizing V1/V2 antibodies may play a role in protection,
probably via antibody-dependent cellular cytotoxicity or other
as yet unidentiﬁed mechanisms (Bonsignori et al., 2012; Haynes
et al., 2012; Su and Moog, 2014). The potential for induction
of such antibodies by VLPs will be of interest for further
investigation.Materials and methods
Ethics statement
Guinea pigs were sterile housed and maintained according to
Emory University School of Medicine guidelines, and all animal
studies were approved by the Emory University Institutional
Animal Care and Use Committee (IACUC).Modiﬁed Env constructs
Plasmid pBlueSF162 containing the SF162 env gene (accession
number EU 123924) was provided by Sang-Moo Kang (Georgia
State University, Atlanta GA). Plasmid pcr3.1-53M21-env contain-
ing the ZM53 env gene (accession number AY 423984) (Derdeyn
et al., 2004) was provided by E Hunter and J Blackwell (Emory
University, Atlanta GA). SIV and HIV-1 env coding sequences were
modiﬁed by replacing the TMS-CT domains of SIVmac239, SF162
SF or ZM53 HIV-1 Envs with domains from other viral glycopro-
teins such as baculovirus (BV) gp64, inﬂuenza virus hemagglutinin
(HA), parainﬂuenza virus-5 fusion protein (F) (Wang et al., 2007)
or a modiﬁed shortened 22 aa MMTV anchored TM-CT or wild
type (WT) HIV-1 TM-CT with a truncated 17 aa cytoplasmic tail
(CT-17). In addition a GCN4 sequence with the propensity to form
a three-helix bundle (Harbury et al., 1993) was added to the
C-terminus of Env with a GSGG linker between the CT domains
(ZM53/701 Gln or SF162/713 Pro) and the GCN4 sequence (Vzorov
and Compans, 2011). The pcDNA3.1(þ) vector (Invitrogen Cor-
poration, Camarillo, CA), was used to express Env constructs.
Cell surface expression assay
Surface expression of the modiﬁed HIV Env proteins transiently
expressed in Hep2 cells was detected by a surface biotinylation
* *
*
*
*
*
* ***
****
3. TMS35-hb
4. TMS22
5. TMS22-hb
1. FL
2. TMS35
Fig. 7. Avidity assay of antibody elicited by immunization with VLPs containing modiﬁed Env. Avidity tests were conducted with serum samples from guinea pigs immunized
by SF162–ZM53 heterologous prime-boost regimen, and collected at 2 weeks following the ﬁnal immunization. Unpaired Student’s t test indicates a signiﬁcant difference
(*Po0.05) between FL group and other groups.
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presence of modiﬁed membrane-anchored Env proteins on cell
surfaces was determined by a cell surface expression assay as
described (Wang et al., 2013). Brieﬂy, Spodoptera frugiperda Sf9
cells were seeded in six-well plates at 1106 cells/well before
infection with rBV at 27 °C for 48 h. After that, cells were washed
three times using cold PBS and incubated with 2 ml of NHS-SS-
biotin dissolved in PBS (0.5 mg/ml) for 30 min at 4 °C. The cells
were then lysed with lysis buffer (150 mM NaCl/50 mM Tris HCl,
pH 7.5/1 mM ethylenediamine tetraacetate/1% Triton X-100/1%
sodium deoxycholate). After centrifugation at 800 g for 10 min,
supernatants were collected and incubated with avidin (Pierce,
Rockford, IL) at 4 °C overnight. The next day, avidin beads were
pelleted and boiled for 5 minutes, and the solubilized proteins
loaded onto sodium dodecyl sulfate-polyacrylamide gels for elec-
trophoresis (SDS-PAGE) and detected with goat anti-HIV-1 gp120
polyclonal antibody (U.S. Biologicals, Massachusetts, MA).
Colorimetric lysate cell fusion assay
Dishes (60-mm diameter) of subconﬂuent NIH3T3 cells were
infected for 1 h with the vTF7-3 virus at an MOI of 1-2 and then
transfected with 4 mg of plasmids for expression of Env constructs.
A second population of 3T3T4R5 cells was infected with wt vac-
cinia virus strain IHD-J and transfected with the pGINT7 ß-Gal
plasmid, which contains the ß-galactosidase (ß-Gal) gene under
the control of the T7 promoter. At 16–20 h post-transfection, thetwo cell populations were suspended, mixed in a 96-well tissue
culture plate and incubated for 2 h 30 min at 37 °C, after which cell
fusion was quantitated by a colorimetric lysate assay (Nussbaum
et al., 1994). The data were analyzed with the Delta Soft II
Microplate analysis program.Production of standard HIV-1 VLPs
Standard HIV VLPs (Env/Gag VLPs) were produced by coinfec-
tion of insect cells (Spodoptera frugiperda Sf9 cells) with rBVs
expressing Env and Gag as described previously (Vassilieva et al.,
2011). VLPs containing Gag only, used as a control, were produced
by infection of Sf9 cells with rBVs expressing Gag. VLPs were
concentrated from the supernatants of Sf9 cell cultures at 62–70 h
post-infection by porous ﬁber ﬁltration using the Quixstand
benchtop system (GE Healthcare, Uppsala, Sweden) followed by
sucrose density gradient ultracentrifugation. The puriﬁed VLPs
were characterized by protein assay, Western blotting, and steri-
lity. A sandwich ELISA was used for Env quantitation (Table 3).
Goat anti-HIV-1 gp120 polyclonal antibody (U.S. Biologicals, Mas-
sachusetts, MA) was used as a coating antibody and a monoclonal
antibody (mAb) HIV-1 gp120 b12 from the AIDS Research and
Reference Reagent Program (ARRRP), Division of AIDS (NIH) was
used as the detection antibody. HIV-1 SF162 gp120 (NIH ARRRP)
was used as a calibration standard. In order to optimize Env
incorporation into VLPs, different MOIs of Env and Gag baculovirus
A.N. Vzorov et al. / Virology 489 (2016) 141–150 149recombinants were used to coinfect cells (Fig. 4B). The ﬁnal pre-
parations of VLPs were normalized by Env content.
Immunization and sample collection
Female guinea pigs were obtained from Charles River Labora-
tory (Wilmington, MA) and immunized (four animals in each
group) two times with SF162 or ZM53 pCAGGS DNA vaccines
(50 mg per guinea pig) separately followed by two boosting
immunizations by the intramuscular (I.M.) route with VLPs using
doses containing 10 mg Env. The amounts of VLP were adjusted
based on % of Env incorporation into VLPs described in Table 3. The
four immunizations were performed at weeks 0, 4, 8, and 12.
Serum samples were collected at weeks 0 (preimmune bleeding),
2 (bleed 1), 6 (bleed 2), 10 (bleed 3) and 14 (bleed 4) by vena cava
bleeding of anesthetized guinea pigs.
Antibody detection by ELISA
Histidine-tagged ZM53 Env and SF162 Env gp120 proteins were
puriﬁed from supernatants of HeLa cells infected with a recom-
binant vaccinia virus expressing these proteins using a nickel bead
column (Blasco and Moss, 1995). Env-speciﬁc antibody (Ab) titers
in immune sera were determined by enzyme-linked immunosor-
bent assay (ELISA) using recombinant ZM53 or SF162 Env gp120
proteins (5 mg/ml) as coating antigens. Ninety-six well microtiter
plates (Nunc-Immuno Plate MaxiSorp™, Nunc Life Technol-
ogies, Basel, Switzerland) were coated with 100 μl of Env protein
(5 mg/ml) in coating buffer (0.1 M sodium carbonate, pH 9.5) at
4 °C overnight. 100 ml of 5000-fold diluted sera were added
to wells to determine ZM53 or SF162 Env-speciﬁc binding Ab
levels. Horseradish peroxidase (HRP)-conjugated goat anti-guinea
pig IgG, IgG1 and IgG2 (Southern Biotechnology, Birmingham, AL)
were used for the determination of serum IgG, IgG1 and
IgG2 titers. Color was developed using the 3,30,5,50-Tetra-
methylbenzidine substrate (Sigma, St. Louis, MO) and the optical
density at 450 nm was read using an ELISA reader (Bio-Rad,
Hercules, CA).
Neutralization assay
Neutralization activity was determined using the JC53-BL
indicator cell assay (Derdeyn et al., 2000). Brieﬂy, preimmune
and immune sera were heat inactivated at 56 °C for 30 min, seri-
ally diluted, incubated with Env pseudotyped virions for 1 h at
37 °C, and then added to JC53-BL cells. β-Galactosidase (β-Gal)-
expressing blue foci indicating infectious spots were counted.
Neutralization was scored by comparing the average ratio of the
number of blue cells in infected wells without treatment with
antibodies to the number in wells where pseudotyped virions
were preincubated with antibodies.
ELISA avidity assay
The avidity index values of serum antibodies for the native viral
envelope were determined by measuring the resistance of
antibody-envelope glycoprotein complexes in the ConA ELISA to
treatment with 1.5 M sodium thiocyanate (NaSCN) (Vermont et al.,
2002). Preparations of pseudotyped virions puriﬁed by ﬁltration,
pelleted and disrupted with 1% Triton X-100 were used as sources
of viral envelope glycoproteins. Brieﬂy, each well of 96-well ConA
plates was coated overnight with 100 ml of a 5 mg/ml (p24) pseu-
dotyped virion suspension (about 0.5 mg/ml Env). Serum samples
were diluted 1:100 in phosphate-buffered saline (PBS) containing
0.1% Tween 80 and threefold serial dilutions of serum samples
were incubated for 90 min at 37 °C. Avidity assays includedparallel enzyme-linked immunosorbent assays, one treated with
PBS and the other with 1.5 M NaSCN for 20 min at room tem-
perature. The avidity index was calculated from the ratio of the
absorbance value obtained with NaSCN treatment to that observed
with PBS treatment multiplied by 100.Statistical analysis
Comparisons among vaccinated groups were performed using a
two-tailed Student’s-test Comparison of neutralization activity
was performed using the Wilkoxon Rank Sum Test. The analyses
were done by using GraphPad Prism version 5.00 for Windows
(GraphPad Software, San Diego, CA). P values of less than 0.05
(Po0.05) were considered to be statistically signiﬁcant.Acknowledgments
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